<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04533763</url>
  </required_header>
  <id_info>
    <org_study_id>201911073</org_study_id>
    <nct_id>NCT04533763</nct_id>
  </id_info>
  <brief_title>Living WELL: A Web-Based Program for Ovarian Cancer Survivors</brief_title>
  <official_title>Living WELL: A Web-Based Program to Improve Quality of Life in Rural and Urban Ovarian Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Susan Lutgendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of a group-based and web-delivered&#xD;
      psychosocial intervention for ovarian cancer survivors (Mindful Living [ML]) compared to a&#xD;
      health promotion condition (Healthy Lifestyles [HL]) in increasing health related quality of&#xD;
      life (HRQOL) and decreasing perceived stress, depressive mood (primary aims), anxiety, and&#xD;
      fatigue (secondary aims) across a 12-month period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Living WELL is a randomized clinical trial examining two different programs for helping&#xD;
      ovarian cancer survivors cope and improve the quality of their lives following treatment. The&#xD;
      programs include techniques and information to enhance both mental and physical well-being.&#xD;
      The study is conducted through an internet video conferencing platform and is open to&#xD;
      survivors in all parts of the US. The purpose of this study is to examine the effects of&#xD;
      various factors such as emotions, stress management and coping techniques, and health&#xD;
      information on quality of life, stress levels, depression, fatigue, and distress in ovarian&#xD;
      cancer survivors. Participants are randomized into either a Mindful Living group (targeting&#xD;
      stress management skills - e.g., relaxation, coping) or a Healthy Lifestyles group (targeting&#xD;
      health promotion strategies - e.g, nutrition, sleep, exercise). Participation in this study&#xD;
      includes taking part in an introductory online meeting, 10 consecutive weekly online&#xD;
      sessions, and follow-up meetings at approximately 4.5 and 9 months following randomization.&#xD;
      Each session will be 1.5-2 hours. Participants will complete surveys online prior to&#xD;
      beginning the program, within a week after the 10-week program is completed, and at 6 months&#xD;
      and 12 months later.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HRQOL from baseline (T1) to T2 (immediate change: post-intervention).</measure>
    <time_frame>Mean change from pre-intervention baseline to T2 (after completion of the 10 week intervention)</time_frame>
    <description>HRQOL will be measured by the Functional Assessment of Cancer Therapy (FACT-O) survey, a health survey designed to assess multiple dimensions of HRQOL. Higher scores indicate better HRQOL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in HRQOL from baseline (T1) to 6 months post intervention (T3) (Long-term change)</measure>
    <time_frame>Mean change from pre-intervention baseline to 6 months post-baseline (T3)</time_frame>
    <description>HRQOL will be measured by the Functional Assessment of Cancer Therapy (FACT-O) survey, a health survey designed to assess multiple dimensions of HRQOL. Higher scores indicate better HRQOL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in HRQOL from baseline (T1) to 12 months post intervention (T4) (Long-term change)</measure>
    <time_frame>Mean change from pre-intervention baseline to 12 months post-baseline (T4)</time_frame>
    <description>HRQOL will be measured by the Functional Assessment of Cancer Therapy (FACT-O) survey, a health survey designed to assess multiple dimensions of HRQOL. Higher scores indicate better HRQOL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Perceived Stress from baseline (T1) to T2 (immediate change: post-intervention).</measure>
    <time_frame>Mean change from pre-intervention baseline to T2 (after completion of the 10 week intervention)</time_frame>
    <description>Perceived Stress will be measured by the Perceived Stress Scale (PSS) a scale commonly used to assess subjective levels of stress. Higher scores indicate more stress.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Perceived Stress from baseline (T1) to 6 months post intervention (T3) (Long-term change)</measure>
    <time_frame>Mean change from pre-intervention baseline to 6 months post-baseline (T3)</time_frame>
    <description>Perceived Stress will be measured by the Perceived Stress Scale (PSS) a scale commonly used to assess subjective levels of stress. Higher scores indicate more stress.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Perceived Stress from baseline (T1) to 12 months post intervention (T4) (Long-term change)</measure>
    <time_frame>Mean change from pre-intervention baseline to 12 months post-baseline (T4)</time_frame>
    <description>Perceived Stress will be measured by the Perceived Stress Scale (PSS) a scale commonly used to assess subjective levels of stress. Higher scores indicate more stress.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in CESD (depressive mood) from baseline (T1) to T2 (immediate change: post-intervention).</measure>
    <time_frame>Mean change from pre-intervention baseline to T2 (after completion of the 10 week intervention)</time_frame>
    <description>Depressive Mood will be measured by the Center for Epidemiological Studies Depression (CES-D) scale. Higher scores indicate higher levels of depressive mood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in CESD (depressive mood) from baseline (T1) to 6 months post intervention (T3)</measure>
    <time_frame>Mean change from pre-intervention baseline to 6 months post-baseline (T3)</time_frame>
    <description>Depressive Mood will be measured by the Center for Epidemiological Studies Depression (CES-D) scale. Higher scores indicate higher levels of depressive mood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in CESD (depressive mood) from baseline (T1) to 12 months post intervention (T4) (Long-term change)</measure>
    <time_frame>Mean change from pre-intervention baseline to 12 months post-baseline (T4)</time_frame>
    <description>Depressive Mood will be measured by the Center for Epidemiological Studies Depression (CES-D) scale. Higher scores indicate higher levels of depressive mood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety from baseline (T1) to 6 months post intervention (T3)</measure>
    <time_frame>Mean change from pre-intervention baseline to T2 (after completion of the 10 week intervention)</time_frame>
    <description>Anxiety will be measured by the Profile of Mood States short form Anxiety subscale. Higher scores indicate greater anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety from baseline (T1) to 6 months post intervention (T3)</measure>
    <time_frame>Mean change from pre-intervention baseline to 6 months post-baseline (T3)</time_frame>
    <description>Anxiety will be measured by the Profile of Mood States short form Anxiety subscale. Higher scores indicate greater anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety from baseline (T1) to 12 months post intervention (T4) (Long-term change)</measure>
    <time_frame>Mean change from pre-intervention baseline to 12 months post-baseline (T4)</time_frame>
    <description>Anxiety will be measured by the Profile of Mood States short form Anxiety subscale. Higher scores indicate greater anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fatigue from baseline (T1) to T2 (immediate change: post-intervention).</measure>
    <time_frame>Mean change from pre-intervention baseline to T2 (after completion of the 10 week intervention)</time_frame>
    <description>Fatigue will be measured by the Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-F). Higher scores represent lower levels of fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fatigue from baseline (T1) to 6 months post intervention (T3)</measure>
    <time_frame>Mean change from pre-intervention baseline to 6 months post-baseline (T3)</time_frame>
    <description>Fatigue will be measured by the Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-F). Higher scores represent lower levels of fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fatigue from baseline (T1) to 12 months post intervention (T4) (Long-term change</measure>
    <time_frame>Mean change from pre-intervention baseline to 12 months post-baseline (T4)</time_frame>
    <description>Fatigue will be measured by the Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-F). Higher scores represent lower levels of fatigue.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Statistical correlations between change in stress management skills, mindfulness, cognitive coping, acceptance, and relaxation frequency and changes in HRQOL, Depressive Mood, Perceived Stress, anxiety and fatigue.</measure>
    <time_frame>Mean change from pre-intervention baseline to completion of the 10 week intervention (T2), 6 months post-baseline,12 months post-baseline</time_frame>
    <description>Stress management skills will be assessed using the Measure of Current States (MOS), Mindfulness skills will be assessed using the Freiburg Mindfulness Inventory, Cognitive Coping Skills will be assessed using the Brief COPE, Acceptance Skills will be assessed using the Acceptance and Action Questionnaire (AAQII), Relaxation frequency will be assessed by a web-based counter documenting frequency of relaxation practice.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Mindful Living (ML)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mindful Living Intervention A 10-week group-based and web-delivered psychosocial intervention targeting key concerns of ovarian cancer survivors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Lifestyles (HL)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy Lifestyle Intervention A 10-week group-based and web-delivered intervention providing information on health promotion for ovarian cancer survivors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Technology-based Mindful Living program</intervention_name>
    <description>The program is delivered using web-based group conferencing. During each session, participants are taught new stress management and coping techniques. Each week there is opportunity to apply techniques to real world situations for practice. Participants have a group orientation session, and then meet for 10 weeks. Group sessions last 1.5 - 2 hours. Booster sessions occur approximately 4.5 and 9 months post- randomization. Program includes training in mindfulness, cognitive behavioral stress management, relaxation, imagery, prioritizing meaningful activities, communication, and coping strategies. Content is geared toward concerns of cancer survivors.</description>
    <arm_group_label>Mindful Living (ML)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Technology-based Healthy Lifestyles program</intervention_name>
    <description>The program is delivered using web-based group conferencing. Sessions include content from the National Cancer Institute, American Cancer Society, and health care providers with expertise in oncology. All content is geared to promoting healthy living among ovarian cancer survivors. Participants have a group orientation session, and then meet for 10 weeks, with group sessions lasting 1.5 - 2 hours. Booster sessions occur approximately 4.5 and 9 months post-randomization. Healthy Lifestyle sessions include topics such as nutrition, exercise, sleep, quality of life, survivorship, and cognitive function with content geared toward concerns of cancer survivors.</description>
    <arm_group_label>Healthy Lifestyles (HL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women between 18 and 90 years of age with a cytological or histological diagnosis of&#xD;
             any stage of epithelial ovarian cancer, peritoneal cancer, fallopian tube cancer or&#xD;
             cancer of Mullerian origin consistent with ovarian/fallopian tube/peritoneal origin&#xD;
             (not consistent with endometrial cancer).&#xD;
&#xD;
          -  Women who have completed primary treatment (surgery and chemotherapy or chemotherapy&#xD;
             alone for a new diagnosis of ovarian/peritoneal/fallopian tube cancer within the last&#xD;
             3 years). Date of completion of primary treatment is defined as within approximately&#xD;
             60 days after the last chemotherapy infusion. Maintenance therapy infusions do not&#xD;
             count in determining date of completion of primary therapy. Women who were not&#xD;
             recommended to receive adjuvant chemotherapy (for example, in the case of certain&#xD;
             stage IA/IB cancers) are eligible after surgery alone. Women receiving consolidation&#xD;
             or maintenance therapy following primary chemotherapy or following treatment for first&#xD;
             recurrence are eligible.&#xD;
&#xD;
          -  Survivors must not have had more than one recurrence. Those who have had one&#xD;
             recurrence will be eligible if they have completed active therapy for their&#xD;
             recurrence.&#xD;
&#xD;
          -  Although most women meeting the above criteria will be in remission, complete clinical&#xD;
             remission (normal tumor markers and normal CT scan) is not a requirement for&#xD;
             eligibility. Even women with low-level disease after completion of cytotoxic&#xD;
             chemotherapy who do not meet the strict definition of remission may have stable&#xD;
             disease and may not require additional cytotoxic chemotherapy for a prolonged period&#xD;
             of time, particularly if they are on maintenance therapy. If subjects recur during the&#xD;
             group they will be allowed to continue to participate, as able, even while taking&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Survivors must be fluent in spoken English (6th grade level), which is necessary to&#xD;
             participate in the intervention.&#xD;
&#xD;
          -  Survivors must be willing to be randomized and followed for 12 months.&#xD;
&#xD;
          -  Survivors must be able to understand and willing to sign a written informed consent&#xD;
             document.&#xD;
&#xD;
          -  Survivors currently involved in the STEPS through Ovarian Cancer program will need to&#xD;
             wait until their involvement is completed to participate.&#xD;
&#xD;
          -  Survivors currently involved in a study involving another behavioral intervention or&#xD;
             an exercise intervention must wait until the prior study is completed to participate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-epithelial ovarian cancer, ovarian tumors of low malignant potential&#xD;
             (&quot;borderline&quot;), cancers originating from other organs.&#xD;
&#xD;
          -  History of prior inpatient psychiatric treatment for severe mental illness (e.g.&#xD;
             psychosis) or current psychosis, history of bipolar disorder or schizophrenia in the&#xD;
             last 2 years or current bipolar disorder or schizophrenia, current major depression,&#xD;
             history of substance use disorder in the last 2 years or current substance dependence,&#xD;
             organic mental disorder (e.g., dementia), or substance use disorder in the last 2&#xD;
             years.&#xD;
&#xD;
          -  Patients who are younger than 18 or older than 90 years of age&#xD;
&#xD;
          -  Unable to meet study requirements&#xD;
&#xD;
          -  Currently receiving primary chemotherapy.&#xD;
&#xD;
          -  History of depression is not excluded as long as the patient is not currently&#xD;
             depressed.&#xD;
&#xD;
          -  Patients who are currently depressed as indicated by a CES-D Score â‰¥ 24&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan K Lutgendorf, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sharaf Zia, MA</last_name>
    <phone>319-467-9780</phone>
    <email>sharaf-zia@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Debra J O'Connell-Moore, MBA</last_name>
    <phone>319-356-1693</phone>
    <email>debra-oconnell-moore@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Castillo</last_name>
      <phone>305-243-7771</phone>
      <email>mnc22@miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Frank J Penedo, PhD</last_name>
      <phone>305-243-1391</phone>
      <email>frank.penedo@miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Frank J Penedo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharif Zia, MA</last_name>
      <phone>319-467-9780</phone>
      <email>sharaf-zia@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Debra J O'Connell-Moore, MBA</last_name>
      <phone>319-356-1693</phone>
      <email>debra-oconnell-moore@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Susan Lutgendorf, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enna Manhardt</last_name>
      <phone>206-616-3913</phone>
      <email>ennahun@uw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathryn Pennington, MD</last_name>
      <phone>206-543-3669</phone>
      <email>adminonc@uw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kathryn Pennington, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Susan Lutgendorf</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>behavioral</keyword>
  <keyword>mindfulness</keyword>
  <keyword>lifestyle</keyword>
  <keyword>CBT</keyword>
  <keyword>health promotion</keyword>
  <keyword>telemedicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 29, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT04533763/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 10, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT04533763/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

